The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | ALYCANTE: axi-cel as second-line therapy for transplant-ineligible patients with R/R LBCL
In this video, Roch Houot, MD, PhD, University of Rennes, Rennes, France, discusses results from the Phase II ALYCANTE trial (NCT04531046), which is evaluating axicabtagene ciloleucel (axi-cel) as second-line therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who are ineligible for stem cell transplant. The study reported a benefit in the axi-cel group with respect to progression-free survival (PFS), complete metabolic response (CMR), and complete remission (CR). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite/Gilead: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Honoraria; MSD: Honoraria; Takeda: Honoraria; Roche: Honoraria; Bristol-Myers Squibb/Celgene: Membership on an entity’s Board of Directors or advisory committees; ADC Therapeutics: Membership on an entity’s Board of Directors or advisory committees; Miltenyi: Membership on an entity’s Board of Directors or advisory committees.
